{"id":"azithromycin-ribaroxaban-paracetamol","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbance (nausea, diarrhea)"},{"rate":null,"effect":"Bleeding (rivaroxaban-related)"},{"rate":null,"effect":"Hepatotoxicity (paracetamol-related)"},{"rate":null,"effect":"QT prolongation (azithromycin-related)"}]},"_chembl":{"chemblId":"CHEMBL5592090","moleculeType":null,"molecularWeight":"152.15"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Azithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Rivaroxaban is a direct Factor Xa inhibitor that prevents thrombin generation and blood clot formation. Paracetamol inhibits prostaglandin synthesis in the central nervous system, reducing pain and fever. The combination addresses infection, thrombotic risk, and symptom management simultaneously.","oneSentence":"This is a fixed-dose combination of three drugs: azithromycin (a macrolide antibiotic), rivaroxaban (an anticoagulant), and paracetamol (an analgesic/antipyretic) that work through distinct mechanisms.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:03:26.371Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Infection with concurrent thrombotic risk requiring anticoagulation and symptom management (indication not clearly defined in public literature)"}]},"trialDetails":[{"nctId":"NCT04673214","phase":"PHASE3","title":"Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment","status":"COMPLETED","sponsor":"Gilberto Cruz Arteaga","startDate":"2020-12-16","conditions":"Covid19","enrollment":114}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["without Ivermectin"],"phase":"phase_3","status":"active","brandName":"Azithromycin / Ribaroxaban / Paracetamol","genericName":"Azithromycin / Ribaroxaban / Paracetamol","companyName":"Gilberto Cruz Arteaga","companyId":"gilberto-cruz-arteaga","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a fixed-dose combination of three drugs: azithromycin (a macrolide antibiotic), rivaroxaban (an anticoagulant), and paracetamol (an analgesic/antipyretic) that work through distinct mechanisms. Used for Infection with concurrent thrombotic risk requiring anticoagulation and symptom management (indication not clearly defined in public literature).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}